After assuming on an interim basis the leadership role for Polpharma, Peter was re-appointed to the board of directors of Polpharma. APP is having a longstanding relationship with the privately held CEE-specialist and conducted a series of strategic projects for Polpharma in the field of Biosimilars, process re-engineering, repositioning of Polpharmas B2B business and other strategic initiatives.